2021 American Transplant Congress
Pill Burden in Belatacept versus Tacrolimus-Based Immunosuppression
*Purpose: Medication non-adherence is a major barrier amongst renal transplant recipients, and improvement can be seen after reduction in pill burden. Belatacept versus tacrolimus-based immunosuppression…2021 American Transplant Congress
Dual-Agent Induction Therapy for Pancreas Transplantation: A Single-center Experience
*Purpose: The optimal induction strategy in pancreas transplantation has not been elucidated. Available evidence supports use of both basiliximab and lymphocyte depleting agents. Rabbit anti-thymocyte…2021 American Transplant Congress
Combined CD11b/CD40 Blockade is Superior to CD40 Blockade Alone in Prolonging Survival in Pig-to-Nonhuman Primate Renal Xenotransplantation
*Purpose: Blockade of the CD40/CD154 pathway is highly effective in preventing rejection in pig-to-nonhuman primate (NHP) xenotransplantation models. Clinical translation of anti-CD154 mAbs, however, has…2021 American Transplant Congress
Infectious Complications After Belatacept Conversion in Kidney Transplant
*Purpose: Tacrolimus (tac), a calcineurin inhibitor, is associated with multiple adverse effects when used for immunosuppression following kidney transplant (KT). Belatacept (bela) is a monoclonal…2021 American Transplant Congress
CD40 Blockade by the Fc-Silent Immunosuppressive Antibody Iscalimab Results in Diminished B Cell Activation and Differentiation and is Paralleled by Whole Blood Gene Expression Data
1Erasmus MC, Rotterdam, Netherlands, 2Novartis Pharmaceuticals AG, Basel, Switzerland
*Purpose: Blockade of costimulatory molecule CD40 by the Fc-silent immunosuppressive drug Iscalimab has shown to inhibit acute alloreactivity in non-human primates and is currently being…2021 American Transplant Congress
Clinical Impact of Transplant Pharmacists on the Care of Solid Organ Transplant Recipients
1Temple University Hospital, Philadelphia, PA, 2Temple School of Pharmacy, Philadelphia, PA
*Purpose: The United Network for Organ Sharing (UNOS) and Centers for Medicare and Medicaid Services (CMS) requires transplant centers to document the participation of a…2021 American Transplant Congress
Association of Immune Cell Markers with Adverse Outcomes in the First 6 Months Post-pediatric Heart Transplantation
*Purpose: Immunosuppression titration post-orthotopic heart transplant (OHT) is limited to trough level monitoring and does not provide data pertaining to overall state of immunosuppression. Additional…2021 American Transplant Congress
Continuous 24-Hour Antithymocyte Globulin (ATG) for Renal Allograft Rejection: Results of a Randomized Controlled Trial
Houston Methodist Hospital, Houston, TX
*Purpose: For acute renal allograft rejection (AR), ATG is generally administered in the inpatient setting because of the need for intravenous access, patient monitoring, and…2021 American Transplant Congress
Impact of Once-Daily Extended-Release Tacrolimus Intrapatient Variability in Stable Adolescent and Young Adult Renal Transplant Recipients – 3 Year Results
1Children's Hospital Colorado, Denver, CO, 2Helen DeVos Children’s Hospital, Grand Rapids, MI
*Purpose: Successful renal transplantation requires complex medication regimens that rely heavily on strict adherence to be effective. Variability in immunosuppression exposure, specifically tacrolimus, is associated…2021 American Transplant Congress
COVID-19 Transmission within One Year from Pancreas and Kidney Recipients
University of Minnesota, Minneapolis, MN
*Purpose: The current pandemic has created uncertainty surrounding the transmission of COVID-19. It was recently published that in the general population, household contacts have a…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 138
- Next Page »